Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2025 08:00 ET | Source: Turn Therapeutics

Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones

WESTLAKE VILLAGE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology,...
October 20, 2025 08:22 ET | Source: Turn Therapeutics

Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025

LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) today announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders...
October 15, 2025 08:00 ET | Source: Turn Therapeutics

Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors

WESTLAKE VILLAGE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and...
October 14, 2025 12:07 ET | Source: Turn Therapeutics

Turn Therapeutics Appoints Arthur Golden to Board of Directors

WESTLAKE VILLAGE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and...
October 08, 2025 08:00 ET | Source: Turn Therapeutics

Turn Therapeutics to Commence Trading Today on Nasdaq

WESTLAKE VILLAGE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and...